Huang Xi, Dai Jisen, Fournier Jeanine, Ali Aktar M, Zhang Qi, Frenkel Krystyna
Nelson Institute of Environmental Medicine, New York University School of Medicine, 550 First Avenue, New York, NY 10016-6451, USA.
Free Radic Biol Med. 2002 Jan 1;32(1):84-92. doi: 10.1016/s0891-5849(01)00770-5.
Ferrous ion (Fe(2+)) is long thought to be the most likely active species, producing oxidants through interaction of Fe(2+) with oxygen (O(2)). Because current iron overload therapy uses only Fe(3+) chelators, such as desferrioxamine (DFO), we have tested a hypothesis that addition of a Fe(2+) chelator, 2,2'-dipyridyl (DP), may be more efficient and effective in preventing iron-induced oxidative damage in human liver HepG2 cells than DFO alone. Using ferrozine as an assay for iron measurement, levels of cellular iron in HepG2 cells treated with iron compounds correlated well with the extent of lipid peroxidation (r = 0.99 after log transformation). DP or DFO alone decreased levels of iron and lipid peroxidation in cells treated with iron. DFO + DP together had the most significant effect in preventing cells from lipid peroxidation but not as effective in decreasing overall iron levels in the cells. Using ESR spin trapping technique, we further tested factors that can affect oxidant-producing activity of Fe(2+) with dissolved O(2) in a cell-free system. Oxidant formation enhanced with increasing Fe(2+) concentrations and reached a maximum at 5 mM of Fe(2+). When the concentration of Fe(2+) was increased to 50 mM, the oxidant-producing activity of Fe(2+) sharply decreased to zero. The initial ratio of Fe(3+):Fe(2+) did not affect the oxidant producing activity of Fe(2+). However, an acidic pH (< 3.5) significantly slowed down the rate of the reaction. Our results suggest that reaction of Fe(2+) with O(2) is an important one for oxidant formation in biological system, and therefore, drugs capable of inhibiting redox activity of Fe(2+) should be considered in combination with a Fe(3+) chelator for iron overload chelation therapy.
长期以来,人们一直认为亚铁离子(Fe(2+))是最可能的活性物质,它通过Fe(2+)与氧气(O(2))的相互作用产生氧化剂。由于目前的铁过载治疗仅使用Fe(3+)螯合剂,如去铁胺(DFO),我们测试了一个假设,即添加Fe(2+)螯合剂2,2'-联吡啶(DP)在预防铁诱导的人肝癌HepG2细胞氧化损伤方面可能比单独使用DFO更有效。使用亚铁嗪作为铁测量的分析方法,用铁化合物处理的HepG2细胞中的细胞铁水平与脂质过氧化程度密切相关(对数转换后r = 0.99)。单独使用DP或DFO可降低用铁处理的细胞中的铁和脂质过氧化水平。DFO + DP共同作用在预防细胞脂质过氧化方面具有最显著的效果,但在降低细胞中的总铁水平方面效果不佳。使用电子自旋共振(ESR)自旋捕获技术,我们在无细胞系统中进一步测试了可影响Fe(2+)与溶解的O(2)产生氧化剂活性的因素。随着Fe(2+)浓度的增加,氧化剂形成增强,并在5 mM的Fe(2+)时达到最大值。当Fe(2+)浓度增加到50 mM时,Fe(2+)的氧化剂产生活性急剧下降至零。Fe(3+):Fe(2+)的初始比例不影响Fe(2+)的氧化剂产生活性。然而,酸性pH(< 3.5)显著减慢了反应速率。我们的结果表明,Fe(